Text Size

SWOG-8947 Collecting and Storing Blood Samples From Patients With Previously Untreated Non-Hodgkin Lymphoma

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Southwest Oncology Group
ClinicalTrials.gov Identifier:
NCT01000558
First received: October 22, 2009
Last updated: May 17, 2013
Last verified: May 2013
History of Changes
  Purpose

RATIONALE: Collecting and storing samples of blood from patients with cancer to test in the laboratory may help the study of cancer in the future.

PURPOSE: This research study is collecting and storing blood samples from patients with previously untreated non-Hodgkin lymphoma.


Condition Intervention
Lymphoma
 Other: biologic sample preservation procedure

Study Type: Observational
Official Title: Central Lymphoma Serum Repository Protocol

Resource links provided by NLM:

MedlinePlus related topics: Cancer Lymphoma
U.S. FDA Resources

Further study details as provided by Southwest Oncology Group:

Primary Outcome Measures:
  • Establishment of a Centralized Lymphoma Serum Repository for the Southwest Oncology Group [ Time Frame: July 2011 ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

blood and serum for patients consenting to banking on lymphoma treatment studies


Enrollment: 939
Study Start Date: March 2005
Study Completion Date: July 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

  • To establish a central lymphoma serum repository that will serve as a resource to provide specimens for current and future scientific studies.
  • To utilize the Southwest Oncology Group clinical database to perform clinicopathologic correlations with the results of those studies.

OUTLINE: Serum is collected and stored for future correlative studies.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients consenting to 8947 banking of blood and serum

Criteria

DISEASE CHARACTERISTICS:

  • Diagnosis of non-Hodgkin lymphoma

    • Previously untreated disease
    • Patients must meet the eligibility criteria and be registered to a currently active Southwest Oncology Group-coordinated treatment protocol for previously untreated non-Hodgkin lymphoma

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01000558

  Show 203 Study Locations
Sponsors and Collaborators
Southwest Oncology Group
National Cancer Institute (NCI)
Investigators
Study Chair: Richard I. Fisher, MD James P. Wilmot Cancer Center
  More Information

Additional Information:
Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Southwest Oncology Group
ClinicalTrials.gov Identifier: NCT01000558     History of Changes
Other Study ID Numbers: CDR0000390329, SWOG-8947, U10CA032102
Study First Received: October 22, 2009
Last Updated: May 17, 2013
Health Authority: United States: Federal Government

Keywords provided by Southwest Oncology Group:
non-Hodgkin lymphoma

Additional relevant MeSH terms:
Lymphoma
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Neoplasms
 Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases

ClinicalTrials.gov processed this record on June 18, 2013